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C. G. Groth, T. E. Starzl 
Since the first liver transplantation in 
man was performed in Denver in March 
1963, 162 such operations have been per-
formed throughout the world. Approxima-
tely one third of the patients have been 
treated at the University of Colorado Me-
dical Center and the Denver Veterans Ad-
ministration Hospital. This report will dis-
cuss our experience with the indications for 
hepatic replacement, the results obtained 
and the prospects for future improvement. 
Indications 
Replacement of the liver is indicated in 
patients with serious liver disease whose 
life expectancy can be measured in days or 
weeks or perhaps a few months. The rea-
sons for operation in our center are listed 
in Table 1. 
From the Departments of Surgery and Pediat-
rics, University of Colorado School of Medi-
cine and the Veterans Administration Hospital, 
Denver, Colorado. This work was supported 
by research grants from the Veterans Admini-
stration, by grants RR-oOOSl and RR-00069 
from the general clinical research centers pro-
gram of the Division of Research Resouces, 
National Institutes of Health, and by grants 
A/!-10176-01, AI-AM-08898, AM- 07772, and 
HE-09110 of the United States Public Health 
Service. 
We have not transplanted the liver for 
metastatic malignancy, as has been attemp-
ted in other centers, because of the strong 
possibility of other extrahepatic metastases. 
With the exception of one case where the 
tumor was adherent to the pylorus which 
also required resection, we have not perfor-
med transplants for primary hepatic ma-
lignancies which have extended beyond the 
confines of the liver. 
Table 1 Indications for Orthotopic Liver 
Transplantation 
Disease Number of Transplantations 
Biliary Atresia 26· 
Primary Hepatic Tumors 13 
Cirrhosis 9 
Chronic Agressive Hepatitis 5 
Wilson's Disease 2 
lupoid Hepatitis 1 
Retransplantation for severe rejection 4 
Total 60 
"One patient had an incidental hepatoma. 
As our experience has grown we have 
become progressively more disappointed 
with the results of transplantation for pri-
mary malignant disease of the liver as we 
shall indicate later. We now rarely recom-
mend transplantation for this indication. 
----------------
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Fig. 1 a The extremely rapid development of pulmonary metastases in a patient who under-
went liver replacement for hepatoma. A. The chest is clear six days after transplantation. B. 
Twenty-nine days post-operative. Two metastases are visible in the lower left lung field (ar-
rows). C. Five days later the tumor deposits previously seen have grown in size (horizontal 
arrows) and a third focus is now present in the right lobe (vertical arrow). D. Forty-four days. 
Metastatic growths are scattered throughout the lungs (arrows). E. Seventy-four days post-
operative. F. Four months after transplantation. Transient dyspnea was first noticed a few days 
later. The patient died of pulmonary and hepatic insufficiency 143 days after operation. 
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Fig. 1 b Destruction of the hepatic homograft by tumor recurrence, as demonstrated by serial 
technetium liver scans. A. 68 days - The scan appears normal. B. 94 days - The patient had 
become jaundiced. Hepatomegaly is evident. C. 101 days - Multiple areas of poor isotope 
concentration are now visible. D. 111 days - The process has continued its rapid progression. 
By the time of death the homograft was almost completely replaced by tumor. 
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Results 
Long term survival can be achieved after 
liver transplantation. In experiments in dogs 
and pigs we have had many survive mere 
than a. year. One dog is still alive more than 8 
years after transplantation. In our first 42 
patients, in whom a minimum followup of 
12 months was available, 11 survived at 
least one year (Table 2). Three of these 
recipients lived more than 2 years. One pa-
tient, who was the longest survivor in the 
world, died 31,'2 years after transplantation. 
Table 2 11 One-y£ar Survivors after Ortho-
topic Liver Transplantation 
Alive 3, II - Ili6 to 25 /8 years 
Died ~ II - 1 to 31/2 years 
12 Months Cancer' 
12 Months - Serum hepatitis, liver failure 
]4 Months - Cancer 
15 Months - Cancer 
15 Months - Rejection, liver failure 
20 Months - Disseminated nocardia 
infection" 
30 Months - Rejection, liver failure 
42 Months - ? Rejection, liver failure 
'This patient actually died a few days short 
of one year. 
"The homograft showed severe chronic ag-
gressive hepatitis, just as in her previously 
removed native liver. 
At the present time 8 patients are alive 
at 1~I 1. 11 2,31 2,10,14,28, and 34 months 
post-transplantation respectively, 
Primary malignant tumors of the liver. 
In our early experience it was hoped that 
hepatic replacement might be useful thera-
py for primarv malignant tumors of the 
liver. However, as long term survival was 
achieved it became obvious that metastases 
were a major problem. In 6 of 7 patients 
treated for hepatoma and followed from 2 
to 14 months after transplantation meta-
stases appeared in the lungs, brain and 
even in the homografts. 
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An example is the patient in Fig. 1a. He 
was a 15 year old boy from whom a large 
hepatoma was removed. No secondary de-
posits were apparent at the time of trans-
plantation. Twenty-nine days later pulmo-
nary metastases appeared and subsequently 
became larger and more numerous. Serial 
scans of the homograft also showed pro-
gressive replacement with tumor, Fig. lb. 
The patient died of pulmonary and hepatic 
insufficiency 143 days after transplantation. 
At autopsy the lungs and the homograft 
showed extensive invasion by tumor (Figs. 
Ic and 1d). 
Fig. 1 c Lungs showing multiple large meta-
stases. 
Fig, 1 d Invasion and nearly complete destruc-
tion of the liver homograft by recurrent he-
patoma. At autopsy almost all the transplanted 
hepatic tissue was replaced by tumor. (By per-
mission of W. B, Saunders Co., 1969.) 
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This disheartening experience has been 
repeatedly seen in other cases. The sole 
exception was in a child aged almost 4 
years who was operated upon for severe 
congenital biliary atresia. An incidental fin-
ding in the liver specimen was a hepatoma 
about 2 em in diameter. The patient has 
now been followed for close to 21/2 years 
with no clinical, radiologic or serologic (u-
fetoprotein estimations) evidence of recur-
rent tumor. 
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It is possible that slower growing tumors, 
such as cholangiocarcinomas may have a 
;'etter prognosis, but thus far we have not 
treated any such cases. However, we have 
had the opportunity to treat one patient 
with an unusual tumor which does not com-
monly metastasize outside the liver, primarily 
because it usually kills through extensive 
replacement of the hepatic parenchyma lea-
ding to liver failure, or by causing fatal he-
morrhage. The tumor was a hemangioendo-
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Fig. 2 The early course of a 52 year old male who had liver replacement as treatment for a 
hemangioendotheliosarcoma. After transplantation, there was a severe rejection crisis. The 
protracted thrombocytopenia postoperatively is often noted after liver transplantation and is 
probably due to thrombocyte sequestration in the homograft. A LG - horse antilymphocyte 
globulin; SGOT - serum glutamic oxalacetic transaminase in international units; and ARROW 
- 625 milligrams of methyl prednisolone intravenously. (By permission of Surg. Gynec. Obstet. 
133:981, 1971). 
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theliosarcoma. The patient's course is illu-
strated in Fig. 2. At the time of transplan-
tation he was gravely ill with severe he-
patic dysfunction and a serum bilirubin of 
'*0 mgm Uill. Following operation there was 
initial good function of the hepatic homo-
graft. The patient then successfully wea~h­
ered a bout of severe rejection after which 
liver function remained satisfactory for ap-
proximately 3 months when his condition 
deteriorated and he died. 
At autopsy examination, there were nu-
merous metastases in the lungs and the ho-
mograft itself was the seat of large tumor 
deposits. These various experiences with 
hepatic malignancies have made us adopt 
a policy of restricting liver transplantation 
almost exclusively to patients with benign 
hepatic disease. 
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Congenital biliary atresia. Encouraging 
results have been obtained in this group 
of patients. Two patients lived at least one 
year after transplantation, two more sur-
vived more than two years and a further 
patient for 3'/2 years. His course is illustra-
ted in Fig. 3. Despite a very poor tissue 
match the patient had only two minor rejec-
tion episodes in the early postoperative 
period. Thereafter, he enjoyed good health 
and excellent liver function till shortly be-
fore his death. A biopsy of the homograft 
at 914 days showed almost normal liver 
architecture. Terminally the patient devel-
oped a febrile illness which led to massive 
hepatic necrosis and death. It is not known 
for certain whether this was caused by a 
virus infection or was a manifestation of 
late rejection. 
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Fig.3 The early course of a 4 year old child who survived for 31/t years after liver trans-
plantation performed as treatment of congenital biliary atresia. Note the rejection episodes at 
1 month and O1!~ months, which were easily controlled. (By permission of W. B. Saunders 
Co .. 1969.) 
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Fig. 40J Postoperative course of an 11 year old recipient of a liver homograft for cirrhosis 
seconJary to Wilson's disease. A severe reject:on crisis beginning about 3 weeks post-trans-
plantation eventually reversed and hepatic function has been essentially normal since the 
sixth postoperative month. The patient remains in good health almost 3 years after operation. 
Wi/SOIl'S disease. Our experience with li-
ver tr.lnspiantation has given us a better 
uncll'r.,t.lncling of this metabolic disorder. 
The wndition is believed to be caused by 
an en7.yme deficiency which causes distur-
bed copper metabolism leading to its exten-
sive deposition in the liver, basal ganglia, 
the l'IIrneas (Kayser-Fleischer rings) and 
other tissues. The main clinical manifesta-
tions .lre severe cirrhosis, or neurologic 
disturb.lnces or both. Experience with liver 
transplJntation suggests that the enzyme 
defkil'nry may be compensated for by re-
r l•ln·I11,·nt of the diseased liver with a 
Ill'.lli h v 'lne and that copper metabolism 
m.lY ll!' restored to normal. The results in 
one slIlh patient are illustrated in Fig. 4a. 
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-tCXX)1 
§ T 
:= 400i 
~~l o I ~~j 
BIOPsy," H' 
~= M~1--~~~I-~~--~--~~~~~ 
. 320 400 480 520 
Time In days post-transplantation 
Fig. 4 b There was massive urinary excretion 
of copper follOWing transplantation. This la-
sted 6 months. A secondary peak of copper 
excretion occurred in response to a 3-day test 
course of penicillamine. (By permission of 
Lancet 1:505,1971). 
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cirrhosis. After transplantation the homo-
graft underwent the worst rejection crisis 
that we have ever observed in any of our 
liver transplant recipients. The bilirubin ro-
se to almost 50 mgm % with associated rises 
in the alkaline phosphatase. Fortunately, it 
was possible to reverse the immunologic 
reaction and the patient has enjoyed ~ir­
tually normal liver function ever since. He 
is nearly 3 years post-transplantation and 
is attending school. Large amounts of cop-
per were passed in the urine for 6 months 
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after operation (Fig. 4b) and biopsies of the 
homograft at 6, 18 and 30 months showed 
a normal copper concentration within the 
organ. 
Similar results were obtained in the case 
of another boy aged 15 years, who in ad-
dition to advanced cirrhosis had severe 
neurologic symptoms. He is now more than 
a year post-transplantation. One and a half 
months after the operation he developed 
jaundice, and elevations of the SCOT (Fig. 
5) and the alkaline phosphatase. Simultan-
60 90 
Time in days 
weight RM~ 47 kg 
15 year oldd' 
150 180 
Fig.5 Triple drug therapy with cyclophosphamide, prednisone and horse antilymphocyte 
globulin (ALG) in a patient who underwent liver transplantation for Wilson's disease. Rejec-
tion has never been diagnosed postoperatively. The temporary deterioration in hepatic function 
in the second postoperative month was accompanied by Australia antigenemia detected by the 
complement fixation (CF) technique and consequently was thought to be a manifestation of 
serum hepatitis. (By permission of 5urg. Gynec. Obstet. 133: 981, 1971). 
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eously his serum became positive for the 
Australia antigen. He was diagnosed as 
having serum hepatitis and immunosup-
pressive therapy was not increased as 
would have been the case had rejection been 
suspected. The abnormal liver chemistries 
gradually returned to normal and the pa-
tient has remained in good health. This case 
illustrates a vitally important point - that 
post-operative elevation of the bilirubin and 
alkaline phosphatase is not synonymous with 
rejection. In fact, they may also be caused 
by serum hepatitis as in this case, but ob-
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struction of the extrahepatic bile ducts or 
hepatotoxicity of the immunosuppressive 
drugs may be responsible as will be discus-
sed later. It is imperative to establish the 
correct diagnosis as each condition requires 
a different form of treatment. 
Hepatitis. Hepatitis occurs post-trans-
plantation in more than 20 % of our renal 
homograft recipients. As illustrated by the 
last case it may also occur in hepatic homo-
graft patients who are exposed to many 
risks including those imposed by the much 
larger blood transfusions required in liver 
t II. 
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Fig. 6 Orthotopic hepatic transplantation for liver failure caused by chronic aggressive hepa-
titis. The Australia antigen which had been de tectable in multiple serum samples for one year 
before operation, disappeared within hours after removal of the patient's own liver. However, 
the Australia antigen reappeared in her blood stream about 2 months post-transplantation at 
a time when she developed a clinical episode of hepatitis. 
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replacement. In view of these findings is 
there any hope of treating lethal serum 
hepatitis with liver transplantation? In the 
present state of our knowledge it is not 
possible to give a definite answer to t!tis 
question. We have no experience with he-
patic replacement in the treatment of acute 
fulminating hepatitis, although it has been 
unsuccessfully attempted elsewhere. Howe-
ver, we have performed liver replacement 
in cases of hepatic failure caused by chronic 
aggressive hepatitis, Australia antigen po-
sitive. Fig. 6 shows the course of a 28 year 
old woman with this disorder. Her serum had 
been persistently positive for the Australia 
antigen for 2 years. At the time of admis-
sion to the hospital she was gravely ill with 
severe ascites, large pleural effusions, a se-
rum albumin of less than 2 gm/IOO rnl and 
a prothrombin time of less than 20 %. Fol-
lowing transplantation her serum promptly 
became negative for the Australia antigen 
and remained so for approximately 2 
months when it again became positive. Soon 
afterwards her liver chemistries became ab-
normal and it was apparent that she again 
had hepatitis. Despite slowly deteriorating 
liver function she was restored to a useful 
life among her family and friends for 20 
months, when she died of a disseminated 
nocardia infection. At autopsy, there was 
recurrence of chronic aggressive hepatitis. 
T ecJmical problems affecting results. Or-
thotopic liver transplantation is a difficult 
procedure as most of the patients have se-
vere portal hypertension. Removal of the 
recipients own liver is complicated by the 
presence of extensive venous collaterals and 
by coagulation defects. In previous publi-
cations we have mentioned problems with 
anatomic abnormalities, clotting of vascular 
anastomoses, phrenic nerve palsy and other 
hazards. 
In this report we wish to concentrate on a 
complication of biliary drainage which we 
3S 
have encountered in 4 recently treated pa-
tients. Our usual technique of biliary re-
construction is by means of a cholecyst-
duodenostomy after having ligated the com-
mon bile duct distal to its junction with the 
cystic duct (Fig. 7). This area is potentially 
) 
// 
Fig. 7 Orthotopic liver transplantation- cho~ 
lecystoduodenostomy has been performed for 
biliary drainage. G. B. = gall bladder; H. A. = 
hepatic artery; 1. V. C. = inferior vena cava; 
P. V. = portal vein. (By permission of Ann. 
Surg. 168:392, 1968). 
vulnerable and may become obstructed with 
inspissated bile or possibly with cellular 
debris cast off into the lumen in the course 
of rejection. In the 4 recent cases mentioned 
above biliary obstruction developed after an 
initial period of normal bile drainage. Two 
of the patients were operated upon in an 
attempt to relieve the obstruction which 
was confirmed by operative cholangiography 
(Fig. 8). However, surgery was undertaken 
too late and the patients died of hepatic 
damage caused by the obstruction, compli-
cated by ascending cholangitis. In the other 
2 patients the lesion was found at autopsy 
examination. In each case the epithelial cells 
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Cholecystoduodenostomy 
B 
Fig. 8 Cholangiography of a hepatic homograft in which biliary reconstruction was with chole-
cystoduodenostomy. LEFT - Technique of dye injection through a duodenotomy and the 
anastomosis. RIGHT - Obstructed duct system. Despite re-exploration and conversion to 
choledochoduodenostomy, the recipient died of uncontrolled sepsis 46 days after transplan-
tation. 
of the bile ducts were swollen and contai-
ned large numbers of cytomegalovirus in-
clusions, which were also present in the 
large accumulations of intraluminal debris. 
It appears possible that these obstructions 
were caused or at least contributed to by 
cytomegalovirus infection. 
In an attempt to avoid this complication 
choledochoduodenostomy was attempted in 
4 subsequent cases using a new method 
illustrated in Figs. 9a and 9b. However in 
one case the implanted bile duct retracted 
out of the duodenum causing a fatal biliary 
peritonitis. We have since reverted to using 
cholecystoduodenostomy. 
Future Prospects 
As experience has accumulated we have 
learned to avoid many tedmical pitfalls 
which we encountered in our early cases. 
The biliary drainage problems mentioned 
above have made us adopt a policy of ear-
ly exploration in any cases of prolonged 
postoperative jaundice, with cholangiO-
graphy and, if necessary, biliary reconstruc-
tion. If warranted, antiviral therapy with 
cytosine arabinoside will also be instituted. 
It is 'hoped that these measures will im-
prove our long term results. 
Another reason for hope that we may 
improve on our 26 % one year survival fig-
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Fig. 9 a Technique of choledochoduodenosto-
my. After opening the duodenum (A), a sub-
mucosal tunnel is created (8, C) through 
which the homograft common bile duct is 
passed (E). 
ure hinges on new developments in im-
munosuppression. Studies in renal homo-
graft recipients during the past 15 months 
have shown that Imuran can be effectively 
replaced as an immunosuppressive agent by 
small doses of cyclophosphamide, which do 
not appear to be as hepatotoxic. Further-
more, a poorly functioning liver may fail 
to metabolize Imuran properly. Cyclophos-
phamide, on the other hand, is given in its 
metabolically active form and should be 
effective no matter what the state of hepatic 
function. In our most recent experience 
using cyclophosphamide in combination 
with prednisone and ALG, 4 of 5 liver re-
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Fig. 9 b Choledochoduodenostomy (continued). 
The homograft bile duct is secured in place 
with four fine sutures (G, H, I) in such a way 
as to create an everting nipple (J). 
cipients have done well from 1 to 4 months 
after operation. If these preliminary encou-
raging findings are confirmed by further 
experience we may be on the threshold of 
a major new advance in liver transplanta-
tion. 
Summary 
The prime indication for liver replace-
ment is advanced benign hepatic disease. 
A 26 010 one-year survival rate is currently 
being achieved. A voidance of technical pit-
falls and improvements in immunosuppres-
sive therapy may result in better long term 
survival figures. 
38 
References: 
1. Martineau, G., K. A. Porter, 7. Corman, B. 
Launois, G. T. Schroter, W. Palmer, C. W. 
Putnam, C. G. Groth, C. G. H algrimson, I. 
Penn and T. E. Starz!: Delayed biliary duct 
obstruction after orthotopic liver transplan-
tation. Surgery 72, 604-610, 1972. 
2. Penn, 1. and T. E. Starzl: The clinical as-
pects of orthotopic liver transplantation. In: 
Biology and Surgery of Tissue Transplan-
tation, ed. Anderson, J. M. Oxford, Black-
well Scientific Publications, 1970, p. 245 
Experience in Orthotopic Liver Transplantation 
3. Penn, J., C. G. Halgrimson and T. E. Starz!: 
Liver transplantation in man. Ann. N. Y. 
Acad. Sci. 170; 251, 1970 
4. Starzl, T. E. and C. W. Putnam: Experience 
in Hepatic Transplantation. Philadelphia, 
Saunders, 1969 
S. Starzl, T. E., C. W. Putnam, C. G. Halgrim-
son, G. T. Schroter, G. Martzneau, B. Lau-
nois, 7. L. Corman, I. Penn, A. S. Booth 7r., 
C. G. Groth and K. A. Porter: Cyclophos-
phamide and whole organ transplantation 
in human beings. Surg. Gynec. Obstet. 133; 
981, 191 
